ID

30319

Descrizione

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00935792

collegamento

https://clinicaltrials.gov/show/NCT00935792

Keywords

versioni (1)
  1. 28/05/18 28/05/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

28 maggio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Lymphocytic Leukemia NCT00935792

Inglese

Eligibility Lymphocytic Leukemia NCT00935792

1 moduli  
Criteria
Descrizione

Criteria

diagnosis of cll manifested by minimum threshold peripheral lymphocyte count of > 5 x 10^9/l (cll variant) or palpable adenopathy >= 1cm or clinically palpable splenomegaly (sll variant); and immunophenotypic demonstrations of a population of b lymphocytes (as defined by cd19+) which are monoclonal (by light chain exclusion)
Descrizione

Chronic Lymphocytic Leukemia | Lymphocyte Count measurement Peripheral blood | Adenopathy Palpable | Splenomegaly Palpable | B-Lymphocytes monoclonal CD19 positive Immunophenotyping

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023434
UMLS CUI [2,1]
C0200635
UMLS CUI [2,2]
C0229664
UMLS CUI [3,1]
C0497156
UMLS CUI [3,2]
C0522499
UMLS CUI [4,1]
C0038002
UMLS CUI [4,2]
C0522499
UMLS CUI [5,1]
C0004561
UMLS CUI [5,2]
C0746619
UMLS CUI [5,3]
C0882808
UMLS CUI [5,4]
C0079611
cll will be diagnosed if these cells have >= 3 of the following characteristics: cd5+, cd23+, dim surface light chain expression, dim surface cd20 expression, and fish analysis is negative for igh/ccnd1 and/or immunostaining is negative for cyclin d1 expression to exclude mantle cell lymphoma previous treatment for cll progressive disease: symptomatic cll (weight loss>10% within 6 months, extreme fatigue, fevers>38.5 c, drenching night sweats without evidence of infection) or evidence of progressive bone marrow failure (hemoglobin<11g/dl, platelet count<100 x 10^9/l) or massive (>6 cm below left costal margin) or progressive palpable splenomegaly or massive (>10 cm) or measurable and progressive lymphadenopathy
Descrizione

Chronic Lymphocytic Leukemia | B-Lymphocytes CD5 positive | B-Lymphocytes CD23 positive | Other Coding | B-Lymphocytes CD20 positive | IGH-CCND1 Negative FISH | CCND1 gene Expression Negative Other Coding | Mantle cell lymphoma Excluded | Prior Therapy Chronic Lymphocytic Leukemia Progressive Disease | Chronic Lymphocytic Leukemia Symptomatic | Weight decreased Percentage Timespan | Fatigue | Fever | Night sweats Increased | Communicable Disease Absent | Pancytopenia Progressive | Hemoglobin measurement | Platelet Count measurement | Splenomegaly Palpable Massive | Splenomegaly Palpable Progressive | Lymphadenopathy Massive | Lymphadenopathy Measurable Progressive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023434
UMLS CUI [2,1]
C0004561
UMLS CUI [2,2]
C0882892
UMLS CUI [3,1]
C0004561
UMLS CUI [3,2]
C0945924
UMLS CUI [4]
C3846158
UMLS CUI [5,1]
C0004561
UMLS CUI [5,2]
C0882818
UMLS CUI [6,1]
C2354041
UMLS CUI [6,2]
C1513916
UMLS CUI [6,3]
C0162789
UMLS CUI [7,1]
C1413172
UMLS CUI [7,2]
C0017262
UMLS CUI [7,3]
C1513916
UMLS CUI [7,4]
C3846158
UMLS CUI [8,1]
C0334634
UMLS CUI [8,2]
C0332196
UMLS CUI [9,1]
C1514463
UMLS CUI [9,2]
C0023434
UMLS CUI [9,3]
C1335499
UMLS CUI [10,1]
C0023434
UMLS CUI [10,2]
C0231220
UMLS CUI [11,1]
C1262477
UMLS CUI [11,2]
C0439165
UMLS CUI [11,3]
C0872291
UMLS CUI [12]
C0015672
UMLS CUI [13]
C0015967
UMLS CUI [14,1]
C0028081
UMLS CUI [14,2]
C0205217
UMLS CUI [15,1]
C0009450
UMLS CUI [15,2]
C0332197
UMLS CUI [16,1]
C0030312
UMLS CUI [16,2]
C0205329
UMLS CUI [17]
C0518015
UMLS CUI [18]
C0032181
UMLS CUI [19,1]
C0038002
UMLS CUI [19,2]
C0522499
UMLS CUI [19,3]
C0522501
UMLS CUI [20,1]
C0038002
UMLS CUI [20,2]
C0522499
UMLS CUI [20,3]
C0205329
UMLS CUI [21,1]
C0497156
UMLS CUI [21,2]
C0522501
UMLS CUI [22,1]
C0497156
UMLS CUI [22,2]
C1513040
UMLS CUI [22,3]
C0205329
please contact study investigator and/or consult protocol document for specific details on laboratory criteria cd52 expression by cll cells willing to provide mandatory biospecimen samples for research studies as required by the protocol negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only willingness to return to the enrolling institution for follow-up
Descrizione

Laboratory criteria | CLL Cells CD52 Expression | Biospecimen Provide Research study | Childbearing Potential Serum pregnancy test negative | Compliance behavior Follow-up

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0022877
UMLS CUI [1,2]
C0243161
UMLS CUI [2,1]
C0023434
UMLS CUI [2,2]
C0007634
UMLS CUI [2,3]
C1539083
UMLS CUI [2,4]
C0017262
UMLS CUI [3,1]
C2347026
UMLS CUI [3,2]
C1999230
UMLS CUI [3,3]
C0681814
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0430061
UMLS CUI [5,1]
C1321605
UMLS CUI [5,2]
C3274571
ecog performance status (ps) 0, 1, or 2--exceptions: grade 3 allowed if caused by cll and not other co-morbidities provide informed written consent life expectancy >= 3 months
Descrizione

ECOG performance status | Informed Consent | Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2]
C0021430
UMLS CUI [3]
C0023671
exclusion
Descrizione

Exclusion Criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0680251
any of the following comorbid conditions: nyha class iii-iv heart disease, recent myocardial infarction (< 6 months prior to registration), uncontrolled infection, infection with the human immunodeficiency virus (hiv/aids), serological evidence of active hepatitis b infection (hbsag or hbeag positive) or positive hepatitis c serology, as further severe immunosuppression with this regimen may occur
Descrizione

Comorbidity | Heart Disease New York Heart Association Classification | Myocardial Infarction | Communicable Disease Uncontrolled | HIV Infection | Acquired Immunodeficiency Syndrome | Serology positive Hepatitis B | Hepatitis B surface antigen positive | Hepatitis B e antigen positive | Serology positive Hepatitis C | Immunosuppression Severe

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C1275491
UMLS CUI [3]
C0027051
UMLS CUI [4,1]
C0009450
UMLS CUI [4,2]
C0205318
UMLS CUI [5]
C0019693
UMLS CUI [6]
C0001175
UMLS CUI [7,1]
C0242089
UMLS CUI [7,2]
C0019163
UMLS CUI [8]
C0149709
UMLS CUI [9]
C0392390
UMLS CUI [10,1]
C0242089
UMLS CUI [10,2]
C0019196
UMLS CUI [11,1]
C4048329
UMLS CUI [11,2]
C0205082
evidence of active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia other active primary malignancy requiring treatment or that limits survival to =< 2 years any major surgery =< 4 weeks prior to registration concurrent investigational drug therapy any of the following: pregnant women,nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [iud], surgical sterilization, abstinence, etc.)
Descrizione

Autoimmune hemolytic anemia | Autoimmune thrombocytopenia | Constitutional (pure) red blood cell aplasia | Primary malignant neoplasm Treatment required for | Primary malignant neoplasm Limiting Life Expectancy | Major surgery | Pharmacotherapy Investigational | Pregnancy | Breast Feeding | Females & males of reproductive potential Contraceptive methods Unwilling | Condoms | Vaginal contraceptive diaphragm | Contraceptives, Oral | Contraceptive injection | Intrauterine Devices | Female Sterilization | Male sterilization | Sexual Abstinence

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0002880
UMLS CUI [2]
C0242584
UMLS CUI [3]
C2873778
UMLS CUI [4,1]
C1306459
UMLS CUI [4,2]
C0332121
UMLS CUI [5,1]
C1306459
UMLS CUI [5,2]
C0439801
UMLS CUI [5,3]
C0023671
UMLS CUI [6]
C0679637
UMLS CUI [7,1]
C0013216
UMLS CUI [7,2]
C1517586
UMLS CUI [8]
C0032961
UMLS CUI [9]
C0006147
UMLS CUI [10,1]
C4034483
UMLS CUI [10,2]
C0700589
UMLS CUI [10,3]
C0558080
UMLS CUI [11]
C0677582
UMLS CUI [12]
C0042241
UMLS CUI [13]
C0009905
UMLS CUI [14]
C1656586
UMLS CUI [15]
C0021900
UMLS CUI [16]
C0015787
UMLS CUI [17]
C0024559
UMLS CUI [18]
C0036899
concomitant use of the following cyp3a4 strong inhibitors: clarithromycin, nefazodone, telithromycin, aprepitant, indinavir, nelfinavir, diltiazem, borisonazole, itrazonazole, ritonavir, erythromycin, ketoconazole, saquinavir, fluconazole (may be used if drug levels can be monitored)
Descrizione

CYP3A4 Inhibitor | Clarithromycin | nefazodone | telithromycin | aprepitant | Indinavir | Nelfinavir | Diltiazem | Other Coding | Itraconazole | Ritonavir | Erythromycin | Ketoconazole | Saquinavir | Fluconazole

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3830624
UMLS CUI [2]
C0055856
UMLS CUI [3]
C0068485
UMLS CUI [4]
C0907410
UMLS CUI [5]
C1176306
UMLS CUI [6]
C0376637
UMLS CUI [7]
C0525005
UMLS CUI [8]
C0012373
UMLS CUI [9]
C3846158
UMLS CUI [10]
C0064113
UMLS CUI [11]
C0292818
UMLS CUI [12]
C0014806
UMLS CUI [13]
C0022625
UMLS CUI [14]
C0286738
UMLS CUI [15]
C0016277
patients with any known bleeding diathesis (any congenital bleeding disorder that affects platelet function and/or coagulation including von willebrand's disease)
Descrizione

Bleeding tendency | Congenital Bleeding Disorder Affecting Platelet function | Congenital Bleeding Disorder Affecting Blood coagulation | von Willebrand Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2,1]
C3641106
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C1254881
UMLS CUI [3,1]
C3641106
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C0005778
UMLS CUI [4]
C0042974
severely impaired lung function as defined as spirometry and dlco that is 50% of the normal predicted value and/or o2 saturation that is 88% or less at rest on room air receiving anticoagulant therapy
Descrizione

Pulmonary function impairment Severe | Spirometry | Carbon Monoxide Diffusing Capability Test | Oxygen saturation measurement At rest On room air | Anticoagulation Therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0858943
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C0037981
UMLS CUI [3]
C1516251
UMLS CUI [4,1]
C0523807
UMLS CUI [4,2]
C0443144
UMLS CUI [4,3]
C2709070
UMLS CUI [5]
C0003281
Ritorna all'inizio della pagina

Similar models

Eligibility Lymphocytic Leukemia NCT00935792

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Chronic Lymphocytic Leukemia | Lymphocyte Count measurement Peripheral blood | Adenopathy Palpable | Splenomegaly Palpable | B-Lymphocytes monoclonal CD19 positive Immunophenotyping
Item
diagnosis of cll manifested by minimum threshold peripheral lymphocyte count of > 5 x 10^9/l (cll variant) or palpable adenopathy >= 1cm or clinically palpable splenomegaly (sll variant); and immunophenotypic demonstrations of a population of b lymphocytes (as defined by cd19+) which are monoclonal (by light chain exclusion)
boolean
C0023434 (UMLS CUI [1])
C0200635 (UMLS CUI [2,1])
C0229664 (UMLS CUI [2,2])
C0497156 (UMLS CUI [3,1])
C0522499 (UMLS CUI [3,2])
C0038002 (UMLS CUI [4,1])
C0522499 (UMLS CUI [4,2])
C0004561 (UMLS CUI [5,1])
C0746619 (UMLS CUI [5,2])
C0882808 (UMLS CUI [5,3])
C0079611 (UMLS CUI [5,4])
Chronic Lymphocytic Leukemia | B-Lymphocytes CD5 positive | B-Lymphocytes CD23 positive | Other Coding | B-Lymphocytes CD20 positive | IGH-CCND1 Negative FISH | CCND1 gene Expression Negative Other Coding | Mantle cell lymphoma Excluded | Prior Therapy Chronic Lymphocytic Leukemia Progressive Disease | Chronic Lymphocytic Leukemia Symptomatic | Weight decreased Percentage Timespan | Fatigue | Fever | Night sweats Increased | Communicable Disease Absent | Pancytopenia Progressive | Hemoglobin measurement | Platelet Count measurement | Splenomegaly Palpable Massive | Splenomegaly Palpable Progressive | Lymphadenopathy Massive | Lymphadenopathy Measurable Progressive
Item
cll will be diagnosed if these cells have >= 3 of the following characteristics: cd5+, cd23+, dim surface light chain expression, dim surface cd20 expression, and fish analysis is negative for igh/ccnd1 and/or immunostaining is negative for cyclin d1 expression to exclude mantle cell lymphoma previous treatment for cll progressive disease: symptomatic cll (weight loss>10% within 6 months, extreme fatigue, fevers>38.5 c, drenching night sweats without evidence of infection) or evidence of progressive bone marrow failure (hemoglobin<11g/dl, platelet count<100 x 10^9/l) or massive (>6 cm below left costal margin) or progressive palpable splenomegaly or massive (>10 cm) or measurable and progressive lymphadenopathy
boolean
C0023434 (UMLS CUI [1])
C0004561 (UMLS CUI [2,1])
C0882892 (UMLS CUI [2,2])
C0004561 (UMLS CUI [3,1])
C0945924 (UMLS CUI [3,2])
C3846158 (UMLS CUI [4])
C0004561 (UMLS CUI [5,1])
C0882818 (UMLS CUI [5,2])
C2354041 (UMLS CUI [6,1])
C1513916 (UMLS CUI [6,2])
C0162789 (UMLS CUI [6,3])
C1413172 (UMLS CUI [7,1])
C0017262 (UMLS CUI [7,2])
C1513916 (UMLS CUI [7,3])
C3846158 (UMLS CUI [7,4])
C0334634 (UMLS CUI [8,1])
C0332196 (UMLS CUI [8,2])
C1514463 (UMLS CUI [9,1])
C0023434 (UMLS CUI [9,2])
C1335499 (UMLS CUI [9,3])
C0023434 (UMLS CUI [10,1])
C0231220 (UMLS CUI [10,2])
C1262477 (UMLS CUI [11,1])
C0439165 (UMLS CUI [11,2])
C0872291 (UMLS CUI [11,3])
C0015672 (UMLS CUI [12])
C0015967 (UMLS CUI [13])
C0028081 (UMLS CUI [14,1])
C0205217 (UMLS CUI [14,2])
C0009450 (UMLS CUI [15,1])
C0332197 (UMLS CUI [15,2])
C0030312 (UMLS CUI [16,1])
C0205329 (UMLS CUI [16,2])
C0518015 (UMLS CUI [17])
C0032181 (UMLS CUI [18])
C0038002 (UMLS CUI [19,1])
C0522499 (UMLS CUI [19,2])
C0522501 (UMLS CUI [19,3])
C0038002 (UMLS CUI [20,1])
C0522499 (UMLS CUI [20,2])
C0205329 (UMLS CUI [20,3])
C0497156 (UMLS CUI [21,1])
C0522501 (UMLS CUI [21,2])
C0497156 (UMLS CUI [22,1])
C1513040 (UMLS CUI [22,2])
C0205329 (UMLS CUI [22,3])
Laboratory criteria | CLL Cells CD52 Expression | Biospecimen Provide Research study | Childbearing Potential Serum pregnancy test negative | Compliance behavior Follow-up
Item
please contact study investigator and/or consult protocol document for specific details on laboratory criteria cd52 expression by cll cells willing to provide mandatory biospecimen samples for research studies as required by the protocol negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only willingness to return to the enrolling institution for follow-up
boolean
C0022877 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C0023434 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C1539083 (UMLS CUI [2,3])
C0017262 (UMLS CUI [2,4])
C2347026 (UMLS CUI [3,1])
C1999230 (UMLS CUI [3,2])
C0681814 (UMLS CUI [3,3])
C3831118 (UMLS CUI [4,1])
C0430061 (UMLS CUI [4,2])
C1321605 (UMLS CUI [5,1])
C3274571 (UMLS CUI [5,2])
ECOG performance status | Informed Consent | Life Expectancy
Item
ecog performance status (ps) 0, 1, or 2--exceptions: grade 3 allowed if caused by cll and not other co-morbidities provide informed written consent life expectancy >= 3 months
boolean
C1520224 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C0023671 (UMLS CUI [3])
Exclusion Criteria
Item
exclusion
boolean
C0680251 (UMLS CUI [1])
Comorbidity | Heart Disease New York Heart Association Classification | Myocardial Infarction | Communicable Disease Uncontrolled | HIV Infection | Acquired Immunodeficiency Syndrome | Serology positive Hepatitis B | Hepatitis B surface antigen positive | Hepatitis B e antigen positive | Serology positive Hepatitis C | Immunosuppression Severe
Item
any of the following comorbid conditions: nyha class iii-iv heart disease, recent myocardial infarction (< 6 months prior to registration), uncontrolled infection, infection with the human immunodeficiency virus (hiv/aids), serological evidence of active hepatitis b infection (hbsag or hbeag positive) or positive hepatitis c serology, as further severe immunosuppression with this regimen may occur
boolean
C0009488 (UMLS CUI [1])
C0018799 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
C0009450 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0019693 (UMLS CUI [5])
C0001175 (UMLS CUI [6])
C0242089 (UMLS CUI [7,1])
C0019163 (UMLS CUI [7,2])
C0149709 (UMLS CUI [8])
C0392390 (UMLS CUI [9])
C0242089 (UMLS CUI [10,1])
C0019196 (UMLS CUI [10,2])
C4048329 (UMLS CUI [11,1])
C0205082 (UMLS CUI [11,2])
Autoimmune hemolytic anemia | Autoimmune thrombocytopenia | Constitutional (pure) red blood cell aplasia | Primary malignant neoplasm Treatment required for | Primary malignant neoplasm Limiting Life Expectancy | Major surgery | Pharmacotherapy Investigational | Pregnancy | Breast Feeding | Females & males of reproductive potential Contraceptive methods Unwilling | Condoms | Vaginal contraceptive diaphragm | Contraceptives, Oral | Contraceptive injection | Intrauterine Devices | Female Sterilization | Male sterilization | Sexual Abstinence
Item
evidence of active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia other active primary malignancy requiring treatment or that limits survival to =< 2 years any major surgery =< 4 weeks prior to registration concurrent investigational drug therapy any of the following: pregnant women,nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [iud], surgical sterilization, abstinence, etc.)
boolean
C0002880 (UMLS CUI [1])
C0242584 (UMLS CUI [2])
C2873778 (UMLS CUI [3])
C1306459 (UMLS CUI [4,1])
C0332121 (UMLS CUI [4,2])
C1306459 (UMLS CUI [5,1])
C0439801 (UMLS CUI [5,2])
C0023671 (UMLS CUI [5,3])
C0679637 (UMLS CUI [6])
C0013216 (UMLS CUI [7,1])
C1517586 (UMLS CUI [7,2])
C0032961 (UMLS CUI [8])
C0006147 (UMLS CUI [9])
C4034483 (UMLS CUI [10,1])
C0700589 (UMLS CUI [10,2])
C0558080 (UMLS CUI [10,3])
C0677582 (UMLS CUI [11])
C0042241 (UMLS CUI [12])
C0009905 (UMLS CUI [13])
C1656586 (UMLS CUI [14])
C0021900 (UMLS CUI [15])
C0015787 (UMLS CUI [16])
C0024559 (UMLS CUI [17])
C0036899 (UMLS CUI [18])
CYP3A4 Inhibitor | Clarithromycin | nefazodone | telithromycin | aprepitant | Indinavir | Nelfinavir | Diltiazem | Other Coding | Itraconazole | Ritonavir | Erythromycin | Ketoconazole | Saquinavir | Fluconazole
Item
concomitant use of the following cyp3a4 strong inhibitors: clarithromycin, nefazodone, telithromycin, aprepitant, indinavir, nelfinavir, diltiazem, borisonazole, itrazonazole, ritonavir, erythromycin, ketoconazole, saquinavir, fluconazole (may be used if drug levels can be monitored)
boolean
C3830624 (UMLS CUI [1])
C0055856 (UMLS CUI [2])
C0068485 (UMLS CUI [3])
C0907410 (UMLS CUI [4])
C1176306 (UMLS CUI [5])
C0376637 (UMLS CUI [6])
C0525005 (UMLS CUI [7])
C0012373 (UMLS CUI [8])
C3846158 (UMLS CUI [9])
C0064113 (UMLS CUI [10])
C0292818 (UMLS CUI [11])
C0014806 (UMLS CUI [12])
C0022625 (UMLS CUI [13])
C0286738 (UMLS CUI [14])
C0016277 (UMLS CUI [15])
Bleeding tendency | Congenital Bleeding Disorder Affecting Platelet function | Congenital Bleeding Disorder Affecting Blood coagulation | von Willebrand Disease
Item
patients with any known bleeding diathesis (any congenital bleeding disorder that affects platelet function and/or coagulation including von willebrand's disease)
boolean
C1458140 (UMLS CUI [1])
C3641106 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C1254881 (UMLS CUI [2,3])
C3641106 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0005778 (UMLS CUI [3,3])
C0042974 (UMLS CUI [4])
Pulmonary function impairment Severe | Spirometry | Carbon Monoxide Diffusing Capability Test | Oxygen saturation measurement At rest On room air | Anticoagulation Therapy
Item
severely impaired lung function as defined as spirometry and dlco that is 50% of the normal predicted value and/or o2 saturation that is 88% or less at rest on room air receiving anticoagulant therapy
boolean
C0858943 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0037981 (UMLS CUI [2])
C1516251 (UMLS CUI [3])
C0523807 (UMLS CUI [4,1])
C0443144 (UMLS CUI [4,2])
C2709070 (UMLS CUI [4,3])
C0003281 (UMLS CUI [5])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial